A meta-analysis study assessment shows that COVID-19 patients under treatment with IFN-α/β have significant viral clearance, with the reduction of the duration of virus detection in the upper respiratory system and elevate the blood inflammatory factors [127]. The gene discussed is IFNA1; the disease is COVID-19.